8 documents

Read All
07:00 , Sep 7, 2015 |  BC Week In Review  |  Financial News

Panther Biotechnology completes private placement of convertible notes

Panther Biotechnology Inc. (OTCQB:PBYA), Evanston, Ill.   Business: Cancer   Date completed: 2015-08-25   Type: Private placement of convertible notes   Raised: $220,000   Shares outstanding prior: 4.7 million   Investor: Chicago Venture Partners  ...
Read More
07:00 , Aug 24, 2015 |  BC Week In Review  |  Company News

Faulk Pharmaceuticals, Panther Biotechnology deal

Panther completed the acquisition of Faulk’s pharmaceutical assets for 50,000 Panther shares. The shares are valued at $299,500 based on Panther’s close of $5.99 on July 15, before the deal closed. Panther will pay Faulk...
Read More
07:00 , Aug 10, 2015 |  BC Week In Review  |  Company News

Alchemia, Panther Biotechnology deal

Panther will acquire Alchemia’s Alchemia Oncology Pty Ltd. subsidiary in a deal slated to close by late October. The subsidiary’s portfolio includes the HyACT drug delivery technology and HA-Irinotecan for cancer. This year, Panther plans...
Read More
07:00 , Jun 8, 2015 |  BC Week In Review  |  Company News

University of Rochester, Panther Biotechnology deal

The university granted Panther exclusive, worldwide rights to develop and commercialize leukemia candidate TDZD-8 . The kinase inhibitor induces oxidative stress and is in preclinical testing. Panther said financial terms are not disclosed. University of...
Read More
07:00 , Apr 27, 2015 |  BC Week In Review  |  Company News

Faulk Pharmaceuticals, Panther Biotechnology deal

Panther will acquire Faulk’s pharmaceutical assets, including TRF-DOX , for an undisclosed number of Panther shares. TRF-DOX is a ligand-drug conjugate of transferrin glycoproteins and doxorubicin for targeted delivery to tumors. Faulk is eligible for...
Read More
07:00 , Apr 27, 2015 |  BC Week In Review  |  Company News

Northwestern University, Panther Biotechnology deal

Panther exercised a 2014 option to license exclusive, worldwide rights to the university’s numonafide . The preclinical candidate is a small molecule derivative of amonafide, a DNA intercalator and topoisomerase II (TOP2) inhibitor (see BioCentury,...
Read More
07:00 , Sep 15, 2014 |  BC Week In Review  |  Company News

Northwestern University, Panther Biotechnology deal

Panther received an option from the university to license exclusive, worldwide rights to numonafide . The preclinical cancer compound is a small molecule derivative of amonafide, a topoisomerase II (TOP) inhibitor and DNA intercalator. The...
Read More
07:00 , Sep 15, 2014 |  BC Week In Review  |  Financial News

Panther Biotechnology financial update

Panther Biotechnology Inc. (OTCQB:PBYA), Evanston, Ill.   Business: Cancer   Date announced: 2014-09-08   Note: Panther plans to implement a 6-for-1 stock split. The effective date has yet to be determined. The company also hopes...
Read More